CT-1812
CT-1812 is an investigational drug being developed for the treatment of Alzheimer's disease. It is a small molecule that targets the sigma-2 receptor complex, which is believed to play a role in the pathophysiology of Alzheimer's disease by modulating amyloid-beta (Aβ) oligomer binding to neurons.
Mechanism of Action[edit | edit source]
CT-1812 is designed to displace Aβ oligomers from neuronal receptors, thereby preventing the synaptic toxicity associated with these oligomers. The sigma-2 receptor complex, which CT-1812 targets, is involved in cellular processes such as calcium signaling and apoptosis. By modulating this receptor, CT-1812 aims to protect neurons from the toxic effects of Aβ oligomers, which are implicated in the synaptic dysfunction and cognitive decline observed in Alzheimer's disease.
Clinical Development[edit | edit source]
CT-1812 is currently undergoing clinical trials to evaluate its safety, tolerability, and efficacy in patients with Alzheimer's disease. Early-phase trials have shown that CT-1812 is well-tolerated, and ongoing studies are assessing its potential to improve cognitive function and slow disease progression.
Research and Studies[edit | edit source]
Preclinical studies have demonstrated that CT-1812 can effectively displace Aβ oligomers from synaptic receptors in animal models, leading to improved synaptic function and cognitive performance. These promising results have led to the initiation of clinical trials in humans.
Potential Benefits[edit | edit source]
If successful, CT-1812 could offer a novel therapeutic approach for Alzheimer's disease by directly targeting the toxic oligomers that contribute to neuronal damage. This mechanism of action is distinct from other treatments that primarily focus on reducing overall amyloid plaque burden.
Challenges and Considerations[edit | edit source]
The development of CT-1812 faces several challenges, including the need to demonstrate clear clinical benefits in terms of cognitive improvement and disease modification. Additionally, understanding the long-term safety profile of the drug is crucial, given the chronic nature of Alzheimer's disease treatment.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
